| Id: | acc4750 |
| Group: | 1sens |
| Protein: | MPO |
| Gene Symbol: | Mpo |
| Protein Id: | P05164 |
| Protein Name: | PERM_HUMAN |
| PTM: | oxidation |
| Site: | unclear |
| Site Sequence: | |
| Disease Category: | Respiratory system diseases |
| Disease: | Hyperoxic Lung Injury |
| Disease Subtype: | |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | KYC |
| Drug Info: | "KYC is a specific drug, but more detailed information about it is not provided here." |
| Effect: | modulate |
| Effect Info: | KYC treatment → Increased oxidation of MPO → Increased conversion of KYC into KYC thio - radicals → Increased thionation of HMGB1 and MPO → Decreased activity of HMGB1 and MPO → Decreased oxidative stress and inflammatory response |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 33607217 |
| Sentence Index: | 33607217_7 |
| Sentence: | "KYC treatment of hyperoxic pups decreased total HMGB1 in lung lysates, increased KYC thiylation of HMGB1, terminal HMGB1 thiol oxidation, decreased HMGB1 association with TLR4 and RAGE, and shifted HMGB1 in lung lysates from a non-acetylated to a lysyl-acetylated isoform, suggesting that KYC reduced lung cell death and that recruited immune cells had become the primary source of HMGB1 released into the hyperoxic lungs." |
Sequence & Structure:
MGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTSLVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLHVALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMCNNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTDQLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPNDPRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQLGLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLLREHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYRSYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLEGGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYNAWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPLLACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMSNSYPRDFVNCSTLPALNLASWREAS
Select PDB:
| Target | Drug name | MOA | Phase | Status | Disease | Source |
|---|---|---|---|---|---|---|
| MPO | VERDIPERSTAT | Myeloperoxidase inhibitor | 3 | Completed | multiple system atrophy | ClinicalTrials |
| MPO | VERDIPERSTAT | Myeloperoxidase inhibitor | 2 | Completed | multiple system atrophy | ClinicalTrials |
| MPO | VERDIPERSTAT | Myeloperoxidase inhibitor | 2 | Active, not recruiting | amyotrophic lateral sclerosis | ClinicalTrials |
| MPO | VERDIPERSTAT | Myeloperoxidase inhibitor | 2 | Completed | amyotrophic lateral sclerosis | ClinicalTrials |
| MPO | VERDIPERSTAT | Myeloperoxidase inhibitor | 2 | Completed | Parkinson disease | ClinicalTrials ClinicalTrials |
| MPO | VERDIPERSTAT | Myeloperoxidase inhibitor | 1 | Completed | Parkinson disease | ClinicalTrials |
| MPO | VERDIPERSTAT | Myeloperoxidase inhibitor | 1 | Recruiting | semantic dementia | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
